Developing next generation non-replicative HSV-1 vectors for sustainable and more precise gene therapies
Watch this webinar to learn how the challenges with using certain viral vectors in gene therapy has advanced the development of a new generation of precise vectors with sustainable effects. Our experts outline the limitations of existing vectors and how these can be overcome using modified recombinant non-replicative herpes simplex virus-1 (HSV-1) vectors. These vectors have potential to expand future applications for gene therapy.
Rethinking antibody discovery in the age of automation
By Drug Target Review
Pain relief without the risk: why SRP-001 could change everything
By Drug Target Review
Why playing it safe is slowing down drug discovery
By Drug Target Review
The next phase of the multiomics evolution, powered by AI
By Dr Francisco Garcia (SVP of Software & Informatics at…
Beyond the Lab: Clinical Trials
Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.
The next phase of the multiomics evolution, powered by AI
By Dr Francisco Garcia (SVP of Software & Informatics at…
How GPCR-targeting therapies are advancing the fight against inflammatory disease
By Stephan Schann (Chief Scientific Officer at Domain Therapeutics)
A spatial approach to understanding drug dynamics using mass spectrometry…
By Stefan Foser - (Vice President - Bruker Daltonics), Steve…
Solving the disconnect between lab and data scientists: part 1
By Dr Raminderpal Singh (Hitchhikers AI and 20/15 Visioneers)